Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Wyeth
Woman and Man Max 99 years
Wyeth Pharmaceuticals, Inc
Update Il y a 4 ans
A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of rhBMP-2/CPM as an Adjuvant Therapy in Closed Fractures of the Humerus
Demonstrate that fracture union is accelerated in subjects with humeral fractures (proximal, shaft) treated with conservative (nonoperative) therapy SOC and a single dose of rhBMP-2/CPM (either 1.0 or...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose, Safety Study of MYO-029 Administered to Adult Patients with Becker, Facioscapulohumeral and Limb-Girdle Muscular Dystrophy
Primary objective is to evaluate safety of MYO-029 in adult subjects with muscular dystrophy.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Phase 3, Open Label, Trial, Evaluating the safety, tolerability and Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Children Previously Partially Immunized with Prevenar
To assess the pneumococcal immune response induced by 13vPnC when measured 1 month after the infant dose of 13vPnC in Group 1.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
Single-blind, Randomized, Phase 1/2 Trial of the Safety, Tolerability, and Immunogenicity of Meningococcal Group B rLP2086 Vaccine in Healthy Infants
To assess the immunogenicity of 60 ?g, 120 µg and 200 ?g of rLP2086 as measured by serum bactericidal assay (SBA) to MnB strains expressing LP2086 subfamily A and B proteins in healthy infants 1 month...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals, Inc
Update Il y a 4 ans
A Phase 2, Multicenter, Single-Blind, Randomized, Stratified, Standard-of-Care Controlled, Feasibility and Safety Study of rhBMP-2/CPM as an Adjuvant Therapy for Fractures of the Proximal Femur
To demonstrate the safety of administering rhBMP-2/CPM (either 1.0 mg/mL or 2.0 mg/mL) as an adjunct to internal fixation in subjects with fractures of the proximal femur. The key safety outcome is th...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
Update Il y a 4 ans
A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Patients with Indolent (slow-growing) Non-Hodgkin Lymphoma (a type of blood cancer) Who Have Failed Treament with Rituximab and Chemotherapy (a drug that prevents the growth of tumor cells) or Radioimmunotherapy(a drug that kills tumor cells with radiation)
To evaluate the antitumor activity of inotuzumab ozogamicin in subjects with indolent NHL who have relapsed or are refractory to rituximab and chemotherapy, or anti CD-20 radioimmunotherapy (RIT), as ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Randomised, Double-Blind Study Comparing the Safety and Efficacy of Etanercept with Sulphasalazine in Subjects with Ankylosing Spondylitis
To compare the efficacy of etanercept 50 mg once weekly with SSZ 3 g daily in the treatment of AS subjects over 16 weeks. The study hypothesis is that etanercept 50 mg once weekly will demonstrate su...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals France, Wyeth Research Division
Update Il y a 4 ans
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 2 FIXED DOSES (50 mg, 100 mg) OF DESVENLAFAXINE SUSTAINED-RELEASE TABLETS IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS SR in subjects receiving daily doses of 50 mg or 100 mg of DVS SR versus subjects receiving placebo.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
Wyeth
Update Il y a 4 ans
WYETH 3144A2-3003 : Essai de phase 3 randomisé comparant l’efficacité du neratinib à l'association du lapatinib et de la capécitabine, chez des patientes ayant un cancer du sein localement avancé ou métastatique HER2+. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase 3 randomized open-label study of neratinib versus lapatinib plus capecitabine for the treatment of ERBB-2 positive locally advanced or metastatic breast cancer.
Country
France
organs
Sein
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
Update Il y a 4 ans
Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-alfa as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma
To compare the independently assessed progression free survival of subjects with clear cell type renal cell carcinoma (all risk groups) treated with bevacizumab + temsirolimus (experimental) versus be...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
6
7
8
9
10
11
12
13
14
15
Next